妊娠期淋巴管肌瘤病患者管理的相关研究进展

doi:10.3969/j.issn.1674-490X.2025.04.002

摘要/Abstract

摘要： 淋巴管肌瘤病是一种罕见的以肺部弥漫性囊性病变为特征的多系统肿瘤性疾病,多见于育龄女性,在妊娠期间被诊断出淋巴管肌瘤病的患者预后较差,而且针对淋巴管肌瘤病的诊治策略对妊娠有较大的影响,因此淋巴管肌瘤病患者在妊娠期的安全性是一个非常棘手的问题。现对妊娠期淋巴管肌瘤病患者管理相关的研究进展进行综述,希望能为此类患者的健康和良好妊娠结局提供帮助。

关键词: 淋巴管肌瘤病, 妊娠, 管理

Abstract: Lymphangioleiomyomatosis is a rare multisystem tumor-related disease characterized by diffuse cystic lesions in the lungs, which is more common in reproductive-aged women. Pregnant women with Lymphangioleiomyomatosis have a poor prognosis, and the management strategies for lymphangioleiomyomatosis have a significant impact on pregnancy. Therefore, the safety of lymphangioleiomyomatosis patients during pregnancy is a very challenging issue. This review summarizes the research progress on the management of lymphangioleiomyomatosis patients during pregnancy, aiming to provide help for the health and good pregnancy outcomes of these patients.

Key words: lymphangioleiomyomatosis, pregnancy, management

中图分类号:

杨淋,柳巧,黎晓强. 妊娠期淋巴管肌瘤病患者管理的相关研究进展[J]. 医学研究与教育, 2025, 42(4): 10-17.

参考文献

[1] 中华人民共和国国家卫生健康委员会.淋巴管肌瘤病的诊疗指南(2019)[J].中国实用乡村医生杂志,2021,28(3):3-5.DOI: 10.3969/j.issn.1672-7185.2021.03.002.
[2] TRAVISW D, BRAMBILLA E, NICHOLSONA G, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol,2015, 10(9): 1243-1260. DOI: 10.1097/JTO.0000000000000630.
[3] BEE J, FULLER S, MILLER S, et al. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study[J]. Thorax, 2018, 73(4): 369-375. DOI: 10.1136/thoraxjnl-2017-210872.
[4] MCCORMACK F X. Lymphangioleiomyomatosis: a clinical update[J].Chest, 2008, 133(2): 507-516. DOI: 10.1378/chest.07-0898.
[5] JOHNSON S R, TATTERSFIELD A E. Clinical experience of lymphangioleiomyomatosis in the UK[J]. Thorax, 2000, 55(12): 1052-1057. DOI: 10.1136/thorax.55.12.1052.
[6] JOHNSON S R, CORDIER J F, LAZOR R, et al. European Respiratory Society Guidelines for the diagnosis and management of lymphangioleiomyomatosis[J]. Eur Respir J, 2010, 35(1): 14-26. DOI: 10.1183/09031936.00076209.
[7] TAVEIRA-DASILVA A M, JOHNSON S R, JULIEN-WILLIAMS P, et al. Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts[J]. Thorax, 2020, 75(10): 904-907. DOI: 10.1136/thoraxjnl-2020-214987.
[8] WAHEDNA I, COOPER S, WILLIAMS J, et al. Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study[J]. Thorax, 1994, 49(9): 910-914. DOI: 10.1136/thx.49.9.910.
[9] PARK S, LEE E J. Lymphangioleiomyomatosis and mTOR inhibitors in real world:a narrative review[J]. J Thorac Dis, 2023, 15(11): 6333-6344. DOI: 10.21037/jtd-23-778.
[10] KRISTOF A S. mTOR signaling in lymphangioleiomyomatosis[J]. Lymphat Res Biol, 2010, 8(1): 33-42. DOI: 10.1089/lrb.2009.0019.
[11] YU J, HENSKE E P. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the “perfect storm” of pro-metastatic factors in LAM pathogenesis[J]. Lymphat Res Biol, 2010, 8(1): 43-49. DOI: 10.1089/lrb.2009.0020.
[12] PRIZANT H, SEN A, LIGHT A, et al. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs[J]. Mol Endocrinol, 2013, 27(9): 1403-1414. DOI: 10.1210/me.2013-1059.
[13] CARSILLO T, ASTRINIDIS A, HENSKE E P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis[J]. Proc Natl Acad Sci USA, 2000, 97(11): 6085-6090. DOI: 10.1073/pnas.97.11.6085.
[14] GAO L, YUE M M, DAVIS J, et al. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor[J]. Virchows Arch, 2014, 464(4): 495-503. DOI: 10.1007/s00428-014-1559-9.
[15] LU Y Y, LIU X L, ZHANG E, et al. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells[J]. PLoS One, 2020, 15(2): e0228894. DOI: 10.1371/journal.pone.0228894.
[16] GU X X, YU J J, ILTER D, et al. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis[J]. Proc Natl Acad Sci USA, 2013, 110(37): 14960-14965. DOI: 10.1073/pnas.1309110110.
[17] OBERSTEIN E M, FLEMING L E, GÓMEZ-MARIN O, et al. Pulmonary lymphangioleiomyomatosis(LAM): examining oral contraceptive pills and the onset of disease[J]. J Women's Health, 2003, 12(1): 81-85. DOI: 10.1089/154099903321154176.
[18] SUN Y, GU X, ZHANG E, et al. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells[J]. Cell Death Dis, 2014, 5(5): e1231. DOI: 10.1038/cddis.2014.204.
[19] MCCARTHY C, GUPTA N, JOHNSON S R, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management[J]. Lancet Respir Med, 2021, 9(11): 1313-1327. DOI: 10.1016/S2213-2600(21)00228-9.
[20] RYU J H, MOSS J, BECK G J, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment[J]. Am J Respir Crit Care Med, 2006, 173(1): 105-111. DOI: 10.1164/rccm.200409-1298OC.
[21] KHADDOUR K, SHAYUK M, LUDHWANI D, et al. Pregnancy unmasking symptoms of undiagnosed lymphangioleiomyomatosis: case report and review of literature[J]. Respir Med Case Rep, 2018, 26: 63-67. DOI: 10.1016/j.rmcr.2018.11.010.
[22] ALMOOSA K F, RYU J H, MENDEZ J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications[J]. Chest, 2006, 129(5): 1274-1281. DOI: 10.1378/chest.129.5.1274.
[23] BHATIA P, BHATIA K. Pregnancy and the lungs[J]. Postgrad Med J, 2000, 76(901): 683-689. DOI: 10.1136/pmj.76.901.683.
[24] GONANO C, PASQUIER J, DACCORD C, et al. Air travel and incidence of pneumothorax in lymphangioleiomyomatosis[J]. Orphanet J Rare Dis, 2018, 13(1): 222. DOI: 10.1186/s13023-018-0964-6.
[25] TAVEIRA-DASILVA A M, JONES A M, JULIEN-WILLIAMS P, et al. Severity and outcome of cystic lung disease in women with tuberous sclerosis complex[J]. Eur Respir J, 2015, 45(1): 171-180. DOI: 10.1183/09031936.00088314.
[26] COHEN M M, POLLOCK-BARZIV S, JOHNSON S R. Emerging clinical picture of lymphangioleiomyomatosis[J]. Thorax, 2005, 60(10): 875-879. DOI: 10.1136/thx.2004.035154.
[27] AVILA N A, DWYER A J, RABEL A, et al. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features[J]. Radiology, 2007, 242(1): 277-285. DOI: 10.1148/radiol.2421051767.
[28] GUPTA N, FINLAY G A, KOTLOFF R M, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American thoracic society/Japanese respiratory society clinical practice guideline[J]. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348. DOI: 10.1164/rccm.201709-1965ST.
[29] XU K F, ZHANG P, TIAN X L, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis(LAM)[J]. Respir Med, 2013, 107(2): 263-268. DOI: 10.1016/j.rmed.2012.10.006.
[30] HIROSE M, MATSUMURO A, ARAI T, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis[J]. PLoS One, 2019, 14(2): e0212776. DOI: 10.1371/journal.pone.0212776.
[31] GLASGOW C G, AVILA N A, LIN J P, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement[J]. Chest, 2009, 135(5): 1293-1300. DOI: 10.1378/chest.08-1160.
[32] TAVEIRA-DASILVA A M, PACHECO-RODRIGUEZ G, MOSS J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis[J]. Lymphat Res Biol, 2010, 8(1): 9-19. DOI: 10.1089/lrb.2009.0024.
[33] HAYASHI T, KUMASAKA T, MITANI K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses[J]. Hum Pathol, 2016, 50: 34-42. DOI: 10.1016/j.humpath.2015.11.002.
[34] TAVEIRA-DASILVA A M, STYLIANOU M P, HEDIN C J, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone[J]. Chest, 2004, 126(6): 1867-1874. DOI: 10.1378/chest.126.6.1867.
[35] HAYASHIDA M, YASUO M, HANAOKA M, et al. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: an analysis of the Japanese National Research Project on Intractable Diseases database[J]. Respir Investig, 2016, 54(3): 193-200. DOI: 10.1016/j.resinv.2015.11.003.
[36] KOBA T, ARAI T, KITAICHI M, et al. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: a report of 24 consecutive patients[J]. Respirology, 2018, 23(3): 331-338. DOI: 10.1111/resp.13190.
[37] MCCORMACK F X, INOVE Y, MOSS J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis[J]. N Engl J Med, 2011, 364(17): 1595-1606.DOI: 10.1056/nejmoa1100391.
[38] SHEN L S, XU W, GAO J S, et al. Pregnancy after the diagnosis of lymphangioleiomyomatosis(LAM)[J]. Orphanet J Rare Dis, 2021, 16(1): 133. DOI: 10.1186/s13023-021-01776-7.
[39] FAEHLING M, FROHNMAYER S, LESCHKE M, et al. Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis(LAM)on sirolimus[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2011, 28(2): 153-155.
[40] FAEHLING M, WIENHAUSEN-WILKE V, FALLSCHEER S, et al. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis(LAM)[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2015, 32(3): 259-264.
[41] SUN R J, ZHAI R R, MA C L, et al. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway[J]. Cancer Med, 2020, 9(3): 1141-1151. DOI: 10.1002/cam4.2723.
[42] MADHIVANAN K, RAMADESIKAN S, HSIEH W C, et al. Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins[J]. Hum Mol Genet, 2020, 29(10): 1700-1715. DOI: 10.1093/hmg/ddaa086.
[43] CHANG W Y C, CLEMENTS D, JOHNSON S R. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells[J]. Am J Physiol Lung Cell Mol Physiol, 2010, 299(3): L393-L400. DOI: 10.1152/ajplung.00437.2009.
[44] YANAGISAWA S. Treatment of pulmonary lymphangioleiomyomatosis during pregnancy[J]. Am J Respir Crit Care Med, 2018, 197(11): 1506-1507. DOI: 10.1164/rccm.201712-2566LE.
[45] GUPTA N, JOHNSON S R, MOSS J, et al. Reply to yanagisawa: treatment of pulmonary lymphangioleiomyomatosis during pregnancy[J]. Am J Respir Crit Care Med, 2018, 197(11): 1507-1508. DOI: 10.1164/rccm.201801-0043LE.
[46] AGRAWAL A, KARLE E, PATEL T P, et al. A pregnant woman presenting with progressively worsening dyspnea and pneumothorax[J]. Chest, 2020, 157(6): e193-e196. DOI: 10.1016/j.chest.2019.11.035.
[47] WANG Q, LUO M Q, XIANG B, et al. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis[J]. Respir Res, 2020, 21(1): 55. DOI: 10.1186/s12931-020-1316-3.
[48] KAUNDINNYAYANA S, KAMATH A. Doxycycline use and adverse pregnancy or neonatal outcomes: a descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database[J]. Health Sci Rep, 2022, 5(6): e931. DOI: 10.1002/hsr2.931.
[49] OPRESCU N, MCCORMACK F X, BYRNES S, et al. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry[J]. Lung, 2013, 191(1): 35-42. DOI: 10.1007/s00408-012-9419-3.
[50] JOHNSON J, JOHNSON S R. Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use[J]. Thorax, 2019, 74(10): 999-1002. DOI: 10.1136/thoraxjnl-2019-213338.
[51] LE K, STEAGALL W K, STYLIANOU M, et al. Effect of beta-agonists on LAM progression and treatment[J]. Proc Natl Acad Sci USA,2018, 115(5): E944-E953. DOI: 10.1073/pnas.1719960115.
[52] KPODONU J, MASSAD M G, CHAER R A, et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis[J]. J Heart Lung Transplant, 2005, 24(9): 1247-1253. DOI: 10.1016/j.healun.2004.09.013.
[53] MAURER J R, RYU J, BECK G, et al. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry[J]. J Heart Lung Transplant, 2007, 26(12): 1293-1299. DOI: 10.1016/j.healun.2007.09.013.
[54] ZHANG J, LIU D, YUE B Q, et al. A retrospective study of lung transplantation in patients with lymphangioleiomyomatosis: challenges and outcomes[J]. Front Med(Lausanne), 2021, 8: 584826. DOI: 10.3389/fmed.2021.584826.